J Immunother Cancer: Safety analysis of nivolumab in adjuvant treatment of stage III/IV melanoma

At present, in the case of adjuvant treatment of melanoma, there are several treatment options to choose from.

In this trial, patients with stage IIIB-C or IV melanoma after surgical resection received nivolumab (3 mg/kg·2 weeks, n=452) or ipilimumab (10 mg/kg·3 weeks) , After 4 consecutive times, change to once every 12 weeks, n=453) treatment until the full year or disease recurrence, intolerable toxicity or withdrawal from the test

Patients in the nivolumab group received a median of 24 doses of nivolumab (range 1-26), and patients in the ipilimumab group received a median of 4 doses of ipilimumab (1-7)

The occurrence of TRAE at different levels and time periods

In the nivolumab group, from the first dose to the last dose of nivolumab within 100 days, the incidence of TRAE for all grades was 67.

Relapse-free survival of patients with or without TRAE

Whether using landmark analysis, or analysis by the Cox model in the treatment arm, or by comparison with ipilimumab group, it was found no evidence of a correlation between the occurrence of TRAE RFS

Mandala Mario,Larkin James,Ascierto Paolo Antonio et al.